Akero Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Akero Therapeutics Inc (AKRO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Akero Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Akero Therapeutics Inc | - | - | - | Yes |
| Competitors combined (22) | ||||
| High-Confidence Competitors (20) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AKRO Stock Performance relative to its Competitors
AKRO Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ironwood Pharmaceuticals inc | 282.9% | Outperformed |
| 2 | Astria Therapeutics Inc | 282.9% | Outperformed |
| 3 | Regeneron Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Zentalis Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Vertex Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Akero Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Akero Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Akero Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Akero Therapeutics Inc | 4,481.75 | - |
| Vertex Pharmaceuticals Inc | 127,533.65 | 12,587.20 |
| Regeneron Pharmaceuticals Inc | 83,818.44 | 15,534.70 |
| Madrigal Pharmaceuticals Inc | 13,107.79 | 1,283.94 |
| Biolinerx Ltd | 4,955.20 | 1.18 |
| Viking Therapeutics Inc | 2,926.33 | - |
| SUBTOTAL | 243,533.56 | 30,417.51 |
Sign in to see all competitors of Akero Therapeutics Inc .
Sources: Akero Therapeutics Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Akero Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Akero Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Akero Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Sagimet Biosciences inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Merck & Co., Inc. | Company report | 85% |
| Boehringer Ingelheim AG | Company report | 85% |
| GSK plc | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Aligos Therapeutics, Inc. | Company report | 85% |
| Arrowhead Pharmaceuticals, Inc. | Company report | 85% |
| Eisai, Inc. | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Altimmune | Company report | 85% |
| Boston Pharmaceuticals | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| Roche Holding AG | Company report | 85% |
| Alnylam Pharmaceuticals, Inc. | Company report | 85% |
| AstraZeneca PLC/MedImmune LLC | Company report | 85% |
| Eli Lilly and Company | Company report | 85% |
| Novo Nordisk A/S | Company report | 85% |
| Amgen, Inc. | Company report | 85% |
| Sanofi | Company report | 85% |
| Novartis Pharmaceuticals Corporation | Company report | 85% |
| Albireo Pharma, Inc. | Company report | 85% |
| Bristol-Myers Squibb Company, Inc. | Company report | 85% |
| Altimmun | Company report | 85% |
| AbbVie, Inc. | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Cymabay Therapeutics Inc | Company report | 85% |
| Intercept Pharmaceuticals inc | Company report | 85% |
| Genfit S a | Company report | 85% |
| Viking Therapeutics Inc | Company report | 85% |
| Galmed Pharmaceuticals Ltd | Company report | 85% |
| Madrigal Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Akero Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Akero Therapeutics Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Akero Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Astria Therapeutics Inc | Single reportable segment 100.00 % |
| Bicycle Therapeutics Plc | Single reportable segment 100.00 % |
| Jaguar Health Inc | Human Health Segment 95.92 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Akero Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Akero Therapeutics Inc | 4,482 | - | -5,228,929 |
| Vertex Pharmaceuticals Inc | 127,534 | 31,079,506 | 10,877,037 |
| Regeneron Pharmaceuticals Inc | 83,818 | 1,008,092 | 280,902 |
| Madrigal Pharmaceuticals Inc | 13,108 | 1,403,213 | -355,295 |
| Biolinerx Ltd | 4,955 | 49,167 | -84,417 |
| Viking Therapeutics Inc | 2,926 | - | -10,090,491 |
| PEERS TOTAL | 239,052 | 1,664,797 | 395,900 |
Sign in to see all peers for Akero Therapeutics Inc .
Akero Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 61.68 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Akero Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 497 companies in Akero Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Akero Therapeutics Inc ranks #0 of 497 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 863, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,123,408 | 20.42 % |
| 2 | Johnson and Johnson | 623,592 | 11.34 % |
| 3 | Beone Medicines Ltd | 555,569 | 10.10 % |
| 4 | Abbvie Inc | 505,479 | 9.19 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 0 | Akero Therapeutics Inc | 4,482 | 0.00 % |
Market cap and industry share for the rest of Akero Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-12-08.
Akero Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (457 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 16.0x | - |
| P/B | 4.2x | 4.3x | -0.2x |
| Return on Equity | -30.68 % | industry aggregate | -48.29 % |
| Return on Invested Capital | -17.09 % | -4.05 % (avg) | -13.04 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Akero Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Return on Invested Capital | - | -20.85 % | -24.12 % | -23.46 % | -16.53 % | -17.81 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Akero Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 863 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Akero Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Akero Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Akero Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 48.3 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-3.0% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Akero Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Akero Therapeutics Inc | 4.85 | 15.78 | 0.02 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Madrigal Pharmaceuticals Inc | 0.72 | 3.52 | 0.60 |
| Biolinerx Ltd | 0.27 | 1.95 | - |
| Viking Therapeutics Inc | 1.60 | 8.10 | - |
Sign in to see all peers for Akero Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Akero Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Akero Therapeutics Inc | Q3 2025 | - | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | +71.2 % | - |
| Biolinerx Ltd | Q4 2025 | -95.9 % | - |
| Viking Therapeutics Inc | Q2 2026 | - | - |
| PEERS TOTAL | +16.7 % | -10.4 % |
Sign in to see all peers for Akero Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Akero Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Akero Therapeutics Inc | Q3 2025 | - | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | - | - |
| Biolinerx Ltd | Q4 2025 | -97.5 % | -52.8 % |
| Viking Therapeutics Inc | Q2 2026 | - | - |
Sign in to see all peers for Akero Therapeutics Inc .
Akero Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Akero Therapeutics Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Biolinerx Ltd | - | - | - |
| Viking Therapeutics Inc | - | - | - |
Sign in to see all peers for Akero Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Akero Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Akero Therapeutics Inc | - | - |
| Vertex Pharmaceuticals Inc | 29.14 | 10.13 |
| Regeneron Pharmaceuticals Inc | 19.58 | 5.40 |
| Madrigal Pharmaceuticals Inc | - | 10.21 |
| Biolinerx Ltd | - | 4,199.32 |
| Viking Therapeutics Inc | - | - |
| PEERS AVERAGE | 35.09 | 8.01 |
Sign in to see all peers for Akero Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.